Working Paper · Nutritional Biochemistry
How one transcription factor links gut permeability, tryptophan metabolism, seed-oil oxidation, hyperinsulinaemia and B-vitamin status to the circadian collapse of NAD⁺.
Obesity is usually modelled as an energy-balance problem with inflammation as a complication. This paper argues something narrower and more testable: that a single ligand-activated transcription factor, the aryl hydrocarbon receptor (AhR), sits at the point where several independent metabolic insults converge, and that its chronic activation is sufficient to produce the characteristic obese phenotype — impaired fat oxidation, circadian disruption, NAD⁺ depletion, and a gut microbiome that extracts more calories from the same food.
The causal case does not rest on correlation. AhR inhibition prevents Western-diet obesity in mice3, reverses established obesity and steatosis (fatty liver disease)4, and kynurenine-driven AhR signalling alone causes weight gain, liver steatosis and hyperglycaemia5. What makes AhR unusual as a target is that its inputs are dietary: tryptophan catabolism, gut-barrier integrity, membrane fatty-acid composition, insulin pulse pattern and B-vitamin sufficiency each feed it, and each is modifiable at the plate.
Six steps, one per part
Not that AhR explains obesity — that it is the node where several partial explanations turn out to be the same explanation.
Parts I–IV build the mechanism: what AhR does when chronically active, what activates it, the loops that make it self-sustaining, and the downstream damage. Parts V–VI are the intervention half. Caveats are collected in Limitations rather than scattered through the text; where a specific claim is weaker than the prose implies, it carries a grade.
Strong Moderate Animal–in vitro Inferred Contested Speculative
AhR is a ligand-activated transcription factor. At rest it sits in the cytoplasm held by a chaperone complex; when a ligand binds it sheds the chaperones, moves into the nucleus, pairs with a partner protein called ARNT, and switches on a defined set of target genes.
It was discovered as the receptor dioxin (TCDD, the potent AhR agonist used in most of this literature) binds, which is why most of the literature on it is toxicology rather than metabolism. That history is the reason it is under-appreciated as a metabolic node: for decades it was studied as the thing that makes industrial pollutants harmful, not as something the body operates deliberately.
The best way to understand it, though, is as a normal daily rhythm rather than a disease state. AhR is switched on after every meal by insulin signalling and switched off in the late fed state by bile-acid signalling2 — a routine postprandial pulse. The pathology is not that AhR turns on; it is that in obesity it never turns off.
Part of why a single receptor can sit at this many crossroads at once is that it is unusually promiscuous. Most nuclear receptors are locked to one ligand family — the estrogen receptor binds estrogens, PPARγ binds fatty acids. AhR binds bacterial metabolites, tryptophan breakdown products, dietary compounds, oxidation products and xenobiotics alike. Usually described as a quirk; read as a design feature, it is why gut health, diet, pollution exposure and oxidative stress all land on the same switch.
Six outputs matter metabolically. They are worth taking as a set, because the claim of this paper is that the set is the obese phenotype.
How to read it. Left, three tiers of input: things that directly switch AhR on, things that manufacture its dominant ligand, and conditions that remove the brakes. Centre, the activated AhR/ARNT complex on its target genes. Right, the six outputs. The two dashed rust arrows are the reason the system does not settle — two of the outputs loop back and become inputs.
TiPARP (PARP7) is a canonical AhR target gene7. PARP enzymes consume NAD⁺ stoichiometrically while ADP-ribosylating their substrates — each reaction burns one NAD⁺ to attach an ADP-ribose tag to the target protein — so inducing TiPARP is inducing an NAD⁺ drain. Dioxin measurably lowers NAD⁺ in liver and thymus and deactivates SIRT3 downstream, the mitochondrial enzyme that keeps proteins like SDH deacetylated and active6. Strong
CLOCK:BMAL1 is the transcription-factor pair that runs the body's ~24-hour rhythm, setting the timing of sleep, hormone release and metabolic activity. AhR interacts with BMAL1 and displaces CLOCK from the heterodimer; separately it interferes with CLOCK:BMAL1 already bound at E-boxes; and separately again it displaces the coactivators the complex needs8. Three mechanisms, one consequence: dampened Per1 and a flattened clock. Because there is no single point of failure, partial AhR activation produces disproportionate disruption. Strong
CLOCK:BMAL1 disruption is not a metabolism-only concern — the same clock genes are implicated well outside this paper's scope, including in mood-disorder pathophysiology30, which is consistent with one transcription-factor pair sitting upstream of more than one downstream system.
AhR transcribes IDO1, the rate-limiting enzyme that makes kynurenine — a breakdown product of the amino acid tryptophan, not an amino acid itself — which is AhR's own dominant endogenous ligand. This is the tightest of the loops in Part III and the reason the system is hard to exit once running. Strong
In the fed state AhR induces PEMT and GNMT2. PEMT spends three SAM molecules per phosphatidylcholine synthesised — SAM is the cell's universal methyl-group donor, so each PC made costs three separate methyl transfers — each transfer yielding S-adenosylhomocysteine and then homocysteine, whose rise is itself a marker of cardiometabolic risk. GNMT (glycine N-methyltransferase) is a second SAM-consuming methyltransferase induced alongside it. A transient postprandial pulse of this is unremarkable. Sustained, it is a continuous drain on the methyl pool that B12 and folate exist to replenish. PEMT, AhR and phosphatidylcholine are all elevated in simple-steatosis patients2. Moderate
AhR induces CYP1B1, which converts arachidonic acid into mid-chain HETEs (5-, 12-, 15-HETE). Those HETEs activate NF-κB and MAPK and feed back to induce more CYP1B124. One side branch matters here specifically: 12-HETE activates PPARγ, raising SCD1 and monounsaturated-fat synthesis. That is AhR actively pushing membrane composition away from the saturated profile — and SCD1 overexpression lowers NAD⁺ and AMPK activation while SCD1 ablation raises both — Part IV.2 walks through why16. Animal–in vitro
AhR activation by dietary and endogenous ligands raises Firmicutes and lowers Bacteroidetes — two of the dominant bacterial phyla in the human gut. Firmicutes are the better energy harvesters, extracting more calories from identical intake, so the same meal leaves a larger surplus of absorbed energy to be stored as fat. The phylum-level ratio is contested as an obesity marker across human cohorts, though the same Firmicutes shift tracks fat accumulation unambiguously in hibernating animals29, and is reported here as a directional AhR effect, not a diagnostic. Contested
The inputs are not parallel switches. They fall into three categories that fail in different ways, and the distinction matters because it determines what kind of intervention works on each.
Insulin via PKB/Akt. Insulin drives AhR into the nucleus through PI3K/PKB with no ligand involved2. Physiological and self-limiting in health; its pathological form is Loop 2 in Part III. Strong
Kynurenine. IDO1 in inflamed adipose tissue converts tryptophan to kynurenine, which binds the AhR ligand-binding domain. Adipocyte-specific IDO1 depletion abolishes kynurenine accumulation and protects mice against obesity; adipocyte AhR ablation abolishes the effect of kynurenine entirely5. The dominant endogenous route. Strong
4-HNE and oxidised ω-6 phospholipids. Polyunsaturated membrane fatty acids — linoleic and arachidonic acid — carry the double bonds that hydroxyl radicals attack. Peroxidation yields 4-hydroxynonenal, an α,β-unsaturated aldehyde that modifies AhR cysteine residues covalently. Oxidised LDL activates AhR and downregulates circadian transcripts28. Saturated membrane fatty acids have no double bonds and cannot initiate the chain. Inferred
Three upstream conditions never touch AhR directly. They all raise IDO1, and therefore all act through kynurenine: bacterial LPS (lipopolysaccharide, a fragment of the outer wall of gram-negative gut bacteria) crossing a permeable gut barrier and signalling through TLR2/4 to NF-κB3; hypoxia (oxygen starvation) in adipose tissue that has expanded faster than its blood supply can keep up, signalling via HIF-1α; and inflammatory IFN-γ, released by immune cells infiltrating that same inflamed, oxygen-starved fat tissue, signalling via JAK/STAT1.
Calling these separate AhR routes would overstate their independence. What they are is three separate reasons the kynurenine tap runs — which is why gut-barrier repair and anti-inflammatory measures register as AhR interventions at all. Strong
These are not activators. They are the removal of brakes that would otherwise hold a given level of activation in check — which is why two people with identical kynurenine can have different AhR activity.
B12 and folate are direct competitive antagonists at the AhR ligand-binding domain, blocking nuclear localisation, XRE binding and target-gene induction. Deficiency in mice induces AhR transcriptional activity on its own1. Strong
B6 never touches the receptor. As pyridoxal-5-phosphate it is the cofactor for kynureninase, the enzyme that clears kynurenine downstream18. Without it the ligand accumulates — see II.1.
Weak bile-acid signalling removes the physiological off-switch for the postprandial insulin pulse. Bile acids activate hepatic FXR, which induces SHP, and SHP is what actually binds ARNT and blocks AhR/ARNT9. When bile-acid signalling is weak, that shutoff doesn't fire: SHP occupancy at AhR target promoters is reduced in NAFLD patients and obese mice while AhR occupancy rises8. Strong
Kynurenine is not intrinsically harmful. It is an intermediate, and what it becomes depends on whether the enzyme that processes it has its cofactor.
How to read it. Roughly 60 mg of tryptophan yields 1 mg of nicotinamide by the upper route, so an intact kynurenine pathway is a genuine NAD⁺ source. The lower route is the same molecule with the exit blocked. The irony worth noticing: the pathway that makes NAD⁺ when B6 is sufficient destroys it when B6 is not, because accumulated kynurenine activates AhR and AhR induces an NAD⁺-consuming enzyme.
Supplementing 80 mg pyridoxine for eight weeks in overweight and obese women reduced fat mass, visceral adiposity, fasting insulin, HOMA-IR, triglycerides and leptin, and raised adiponectin against control17. The trial measured neither kynurenine nor AhR activity, so the mechanism here is inferred from the enzymology rather than demonstrated by the trial. Inferred
A transcription factor with a working off-switch does not cause chronic disease. What makes AhR different in the obese state is that three of its outputs regenerate its own inputs.
How to read it. All three loops pass through the same central node, which is why they compound rather than add. Loop 1 regenerates the ligand. Loop 2 removes the antagonist. Loop 3 manufactures a second, chemically different ligand out of the redox damage the first two cause. Every individual arrow is documented; none of the three rings has been demonstrated end-to-end in a single experiment.
AhR induces IDO1; IDO1 makes kynurenine; kynurenine activates AhR. The tightest of the three, and the reason kynurenine does not simply decay once the initiating inflammation resolves. Strong
AhR induces PEMT; PEMT spends SAM; regenerating SAM draws on B12 and folate; B12 and folate are the receptor's competitive antagonists. The receptor consumes the molecules that would restrain it. In health this never runs long enough to matter, because FGF19/SHP terminates the pulse. In obesity, with the shutoff blunted and insulin chronically elevated, it runs continuously. Inferred
AhR induces TiPARP; TiPARP depletes NAD⁺; NAD⁺-starved SIRT3 leaves SDH hyperacetylated14; NADH backs up at Complex I and produces superoxide in the forward direction25; the hydroxyl radical that follows attacks membrane polyunsaturated fatty acids; 4-HNE results and activates AhR covalently.
That redox damage has a second exit besides the ligand it makes directly, and this one closes back through insulin rather than through AhR's ligand-binding domain. The same NADH backup is a mitochondrial-overload signature — incomplete fatty-acid oxidation and depleted TCA intermediates, which Koves et al. tie directly to skeletal-muscle insulin resistance31. And the superoxide is not just a stepping-stone to 4-HNE: reactive oxygen species are independently sufficient to cause insulin resistance across several experimental models, an effect reversed by antioxidant treatment32. Either route lands in the same place the ligand does — insulin resistance drives the compensatory hyperinsulinaemia that feeds Tier 1's PKB/Akt route back into AhR, the mechanism in the flag below. So Loop 3 has two closures sharing one upstream cause, not one. Inferred
This loop has a dietary lever the other two do not. Its substrate is membrane ω-6 content, and a saturated-fat-rich membrane cannot sustain the peroxidation chain at all, because there are no double bonds for the radical to attack. Inferred
Hepatic insulin resistance is selective: glucose disposal fails while lipogenic signalling stays intact or amplifies. If the PKB→AhR arm sits on the preserved side — and the fed-state mechanism suggests it does — then AhR activation increases in proportion to how insulin-resistant someone becomes, driven by the compensatory hyperinsulinaemia the resistance itself produces. Speculative The selective-resistance principle is well established; this particular branch has not been quantified in insulin-resistant human liver. What is no longer speculative is that resistance gets there in the first place: Loop 3 supplies a documented route into it — mitochondrial overload and superoxide excess, independent of whatever else is causing resistance elsewhere in the body.
NAD⁺ is not a static pool that happens to be low in obesity. It is manufactured rhythmically. CLOCK:BMAL1 transcribes NAMPT, the rate-limiting enzyme of the salvage pathway; NAMPT makes NMN; NMNAT converts NMN to NAD⁺; NAD⁺ fuels SIRT1; and SIRT1 is recruited back to the NAMPT promoter to sustain synthesis of its own coenzyme1213. Intracellular NAD⁺ oscillates on a 24-hour cycle as a result.
This is what makes AhR's displacement of CLOCK more serious than a timing problem. It shuts down NAMPT transcription, which is the rate-limiting step of NAD⁺ production. The NAD⁺ deficit in obesity is therefore not only a consumption problem — TiPARP, PARP1, CD38 — but a production failure, and the production failure is downstream of AhR.
The human anchor is a monozygotic-twin study: in BMI-discordant identical twins, the heavier co-twin had lower NAD⁺/SIRT pathway expression in adipose tissue, tracking with inflammation and insulin resistance20. Because the twins are genetically identical, the deficit is acquired. The companion study found weight loss raised NAD⁺/SIRT1 and lowered PARP activity21. Moderate
Sleep is the other input here, and no dietary intervention substitutes for it. Delaying sleep onset progressively — without reducing total sleep — collapses circadian transcript expression including CLOCK and BMAL1 severalfold in humans. citation to pin
The second casualty is a thermogenic circuit that runs on saturated fat and only works when NAD⁺ is replete.
How to read it. Follow the top row left to right, then down the right side and back along the bottom — it is a cycle, and the point of the cycle is that it burns energy without making ATP. The superoxide here is a signal, not damage: small, controlled, immediately buffered. Note that it emerges at Complex I running backwards, not at Complex II. SDH and β-oxidation FADH₂ create the conditions; Complex I produces the radical.
Saturated fatty acids reduce FAD at every carbon pair during β-oxidation. Polyunsaturated fatty acids cannot — their double bonds are already oxidised at those positions — so they yield proportionally less FADH₂ and a less reduced Q pool. The in-vivo evidence is the SCD1 line: mice that cannot convert saturated to monounsaturated fat show higher AMP/ATP, higher AMPK activation and higher NAD⁺ with greater SIRT1 activity, while SCD1 overexpression produces the reverse16. Animal–in vitro
The same NAD⁺/sirtuin gate decides whether the pulse is useful. In an NAD⁺-replete cell SIRT3 keeps SDH functional and the burst is a discrete, buffered H₂O₂ signal. In an NAD⁺-depleted one the circuit is broken at three points at once — SDH acetylated, NNT suppressed23, membranes peroxidisable — and what is produced instead is unbuffered forward-direction superoxide from backed-up NADH. Same organelle, opposite meaning.
Reductive stress is an excess of reducing equivalents, and chronic antioxidant supplementation adds to it. Over-reducing the glutathione couple impairs the redox-sensitive protein chemistry that depends on it, and a reductive-stress → oxidative-stress → reductive-stress feedback has been described27.
The corrective is to lower the NADH:NAD⁺ ratio, not to add more reducing capacity on top of it. Alpha-lipoic acid does exactly that — reduced by lipoamide dehydrogenase in an NADH-dependent reaction, it lowered cellular NADH by about 30% with a smaller and slower effect on NADPH26. It is an electron acceptor, not a scavenger. Moderate
Each lever below acts on a different tier of Part II. The coverage matrix at V.6 is the single place where the mapping is laid out; these sections explain the mechanisms rather than repeat it.
Theabrownin is the dominant bioactive polymer in fermented Pu-erh tea, and its mechanism in humans is unusual: it acts on FXR in two anatomical places with opposite local effects.
In the gut it suppresses bile-salt-hydrolase-active microbes, so conjugated bile acids accumulate in the ileum. These are weak FXR agonists, so intestinal FXR signalling falls and serum FGF19 drops — which sounds like the wrong direction until you follow it: less FGF19 means CYP7A1 stays active, so bile-acid synthesis and turnover stay high. Meanwhile the bile acids reaching the liver through the portal circulation activate hepatic FXR, which induces SHP10. SHP binds ARNT and blocks AhR9.
So theabrownin restores the physiological AhR shutoff — the same SHP-dependent brake that terminates the postprandial insulin pulse in health. It also inhibits α-glucosidase and α-amylase, blunting the glucose rise and therefore the insulin signal that opens the pulse in the first place. One compound acting on both the trigger and the brake of Tier 1's insulin route.
Three further arms, all downstream of Pu-erh's fermentation microbes and polyphenol content: it promotes gut Lactobacillus enrichment, which diverts tryptophan to indoles, competing with IDO1 for substrate11; it also promotes Akkermansia muciniphila enrichment, which tightens the gut barrier and reduces the LPS flux driving Tier 2; and cinnabarinic acid, present in Pu-erh itself, occupies the AhR ligand-binding domain as a partial agonist, competitively displacing kynurenine.
The cholesterol arm is separate and addresses reductive stress rather than AhR. Sustained bile-acid excretion depletes hepatic cholesterol, SREBP-2 responds, and cholesterol synthesis consumes roughly 12–16 NADPH per molecule across the mevalonate pathway — a genuine NADPH sink, shown to lower NAD(P)H and improve function in a complex-I-deficient model15. Moderate for the human FXR/SHP arm; Animal–in vitro for the NADPH sink.
Both flavonols competitively inhibit PARP1 at its NAD⁺ pocket, sparing NAD⁺ that would otherwise be consumed. This complements rather than duplicates the theabrownin arm: theabrownin reduces TiPARP by suppressing its transcription, flavonols reduce PARP1 by inhibiting the enzyme. Two different PARP family members, two different mechanisms.
What the restored NAD⁺ buys is SIRT3 activity, and SIRT3's two relevant substrates are exactly the two failure points in the Part IV circuit: SDHA, which it deacetylates at thirteen identified sites14, and NNT. Restoring both reinstates the RET circuit and — by preventing the NADH backup that generates hydroxyl radicals — reduces the 4-HNE production feeding Loop 3.
Secondary arms: both flavonols activate NRF2, the transcription factor that senses oxidative and electrophilic stress and switches on the cell's antioxidant enzymes in response — glutathione synthesis, thioredoxin reductase (which keeps the thioredoxin system reduced and able to neutralise peroxides) and NQO1 (which detoxifies reactive quinones before they can do damage) — cutting the ROS burden upstream of both PARP activation and lipid peroxidation. Quercetin also inhibits PI3K, reducing PKB (protein kinase B, i.e. Akt) directly — the same insulin-driven arm that opens Tier 1's nuclear-translocation route. SIRT1 deacetylates LKB1, activating AMPK, which improves insulin sensitivity and so lowers the chronic insulin driving Tier 1. Quercetin also inhibits mTORC1 — as does AMPK, via TSC2 and Raptor — promoting mitophagy, and inhibits COMT, slowing catecholamine breakdown and supporting lipolysis. Animal–in vitro for most arms; see Limitations on bioavailability.
B12 and folate are the only interventions here that act at the receptor itself, and their delivery vehicle matters more than usual. Milk B12 is bound to haptocorrin and related binding proteins that survive gut transit and support cubilin-mediated ileal absorption, and its bioavailability exceeds synthetic cyanocobalamin at equivalent dose22b. Milk folate behaves similarly, and milk lowers homocysteine more effectively than matched supplement doses22. Low serum B12 is inversely associated with BMI in a nationally representative US sample after adjustment19.
Whey contributes separately. Dietary tryptophan has two competing fates: the IDO1/kynurenine route this whole paper is about, and a smaller route through tryptophan hydroxylase (TPH) into serotonin and then melatonin. Both enzymes draw on the same circulating tryptophan pool, so when IDO1 is running hot — as this paper's model has it doing throughout obesity — more of that pool is pulled toward kynurenine and less reaches TPH. Whey is the densest dietary tryptophan source per gram of protein, which raises the size of the pool itself rather than trying to out-compete IDO1 for a fixed one; more tryptophan reaching TPH means more serotonin and melatonin, and melatonin is itself a circadian amplitude signal that the Part IV mechanism erodes. Pairing tryptophan-rich protein with B6 compounds this twice over: B6 is the cofactor that converts 5-HTP to serotonin, and — per II.1 — the same cofactor that clears any kynurenine that does form before it accumulates and activates AhR. Whey also preserves lean mass during fat loss and blunts postprandial triglycerides. Asparagus and orange juice cover folate outside dairy. Moderate
Saturated fat does two things nothing else here does. It supplies the high FADH₂:NADH ratio that drives the Part IV thermogenic circuit, and it builds membranes that cannot sustain a peroxidation chain — closing Loop 3 at its substrate rather than downstream of it. Both follow from the same structural fact: no double bonds.
This is where this paper and the linoleic-acid argument meet from opposite directions. That paper's case is that excess ω-6 supplies the oxidisable substrate; this one's is that AhR supplies the oxidant and then consumes the product as a ligand. The 12-HETE → PPARγ → SCD1 branch of I.5 means AhR is also pushing membrane composition toward monounsaturated and away from saturated — the direction that keeps the circuit off. Inferred
Covered in the box at the end of Part IV. Its distinguishing property is that it targets the NADH excess directly rather than scavenging the radicals that excess produces, which makes it the one supplement in this framework that does not carry the reductive-stress objection. Moderate
| Input | Tier | What addresses it, and how |
|---|---|---|
| Kynurenine | Direct | Theabrownin — SHP blocks AhR/ARNT; Lactobacillus diverts tryptophan; cinnabarinic acid competes at the site. B12/folate — competitive antagonism. B6 — clears the ligand downstream. |
| 4-HNE / oxidised ω-6 | Direct | Saturated fat — removes the peroxidisable substrate (primary). Flavonols — NRF2 and restored SIRT3/NNT cut radical production. ALA — lowers the NADH driving it. B12/folate antagonism is not established against covalent modification. |
| Insulin / PKB | Direct | Theabrownin — α-glucosidase inhibition lowers the trigger, FXR/SHP restores the brake. Quercetin — PI3K inhibition. Flavonols — AMPK improves sensitivity, lowering chronic insulin. |
| LPS / gut barrier | Supply | Theabrownin — Akkermansia enrichment and tight-junction integrity. |
| Adipose hypoxia, IFN-γ | Supply | Addressed only indirectly, through fat loss and reduced inflammatory tone. The weakest coverage in the framework. |
| B12 / folate status | Restraint | Milk (superior bioavailability), asparagus, orange juice. |
| B6 status | Restraint | Animal protein, whey. |
| FGF19 / SHP shutoff | Restraint | Theabrownin — hepatic FXR activation restores SHP induction. |
The framework reduces to a short list. None of it requires supplements, and the food-matrix forms are in several cases better absorbed than the isolated compounds.
The restraint-lever nutrients from V.3 and the coverage matrix (V.6), quantified. Amounts are USDA-typical per common serving; %DV uses current adult label values (B12 2.4 μg, folate 400 μg DFE, B6 1.7 mg). Whey's tryptophan density is unusual — most protein sources run closer to 1–1.3% of protein by weight.
| Nutrient | Restraint on | Food, serving | Amount |
|---|---|---|---|
| Vitamin B12 | Kynurenine | Whole milk, 1 cup (240 ml) | ~1.2 μg (~50% DV) — haptocorrin-bound, higher bioavailability than synthetic cyanocobalamin |
| Folate | Kynurenine | Asparagus, 1 cup cooked | ~260 μg (~65% DV) — the richest non-dairy source here |
| Folate | Kynurenine | Orange juice, 1 cup | ~75 μg (~18% DV) — carries a fructose load; time relative to meals |
| Folate | Kynurenine | Whole milk, 1 cup | ~12 μg (~3% DV) — modest per serving, but the vehicle drinkers hit daily |
| Vitamin B6 | Kynurenine | Pastured chicken or beef, 3 oz (85 g) | ~0.4–0.5 mg (~25–30% DV) |
| Tryptophan | Serotonin / melatonin | Whey protein, 1 scoop (~25 g protein) | ~500 mg — densest common source per gram of protein |
| Tryptophan | Serotonin / melatonin | Pastured chicken or turkey, 3 oz (85 g) | ~300 mg |
Moderatefor the amounts — standard USDA per-serving values, but brand, cut, and fortification shift them; this quantifies V.3’s food list, it does not newly establish the antagonism mechanism itself (that's ref 1).
What would break the argument outright is a demonstration that AhR inhibition improves metabolic outcomes only through one of the six outputs rather than the set — that would make AhR a proxy for something narrower rather than the integrator this paper claims it is.